IL281770A - Indane derivatives for use in the treatment of bacterial infection - Google Patents

Indane derivatives for use in the treatment of bacterial infection

Info

Publication number
IL281770A
IL281770A IL281770A IL28177021A IL281770A IL 281770 A IL281770 A IL 281770A IL 281770 A IL281770 A IL 281770A IL 28177021 A IL28177021 A IL 28177021A IL 281770 A IL281770 A IL 281770A
Authority
IL
Israel
Prior art keywords
treatment
bacterial infection
indane derivatives
indane
derivatives
Prior art date
Application number
IL281770A
Other languages
Hebrew (he)
Inventor
Leiris Simon
Thomas Davies David
Everett Martin
SPRYNSKI Nicolas
BEYRIA Lilha
David Pallin Thomas
Peter Cridland Andrew
Jonathan Blench Toby
Leonard Elliott Richard
Edward Clark David
Original Assignee
Antabio Sas
Leiris Simon
Thomas Davies David
Everett Martin
SPRYNSKI Nicolas
BEYRIA Lilha
David Pallin Thomas
Peter Cridland Andrew
Jonathan Blench Toby
Leonard Elliott Richard
Edward Clark David
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP18290106.6A external-priority patent/EP3628666A1/en
Application filed by Antabio Sas, Leiris Simon, Thomas Davies David, Everett Martin, SPRYNSKI Nicolas, BEYRIA Lilha, David Pallin Thomas, Peter Cridland Andrew, Jonathan Blench Toby, Leonard Elliott Richard, Edward Clark David filed Critical Antabio Sas
Publication of IL281770A publication Critical patent/IL281770A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/64Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
IL281770A 2018-09-25 2021-03-24 Indane derivatives for use in the treatment of bacterial infection IL281770A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP18290106.6A EP3628666A1 (en) 2018-09-25 2018-09-25 Indane derivatives for use in the treatment of bacterial infection
EP18290104 2018-09-26
EP18197365 2018-09-27
PCT/EP2019/070115 WO2020064173A1 (en) 2018-09-25 2019-07-25 Indane derivatives for use in the treatment of bacterial infection

Publications (1)

Publication Number Publication Date
IL281770A true IL281770A (en) 2021-05-31

Family

ID=67439236

Family Applications (2)

Application Number Title Priority Date Filing Date
IL281770A IL281770A (en) 2018-09-25 2021-03-24 Indane derivatives for use in the treatment of bacterial infection
IL281780A IL281780A (en) 2018-09-25 2021-03-24 Indane derivatives for use in the treatment of bacterial infection

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL281780A IL281780A (en) 2018-09-25 2021-03-24 Indane derivatives for use in the treatment of bacterial infection

Country Status (14)

Country Link
US (2) US20220112169A1 (en)
EP (2) EP3856729A1 (en)
JP (2) JP7429993B2 (en)
KR (2) KR20210087025A (en)
CN (2) CN113166085B (en)
AU (2) AU2019351551A1 (en)
BR (2) BR112021005651A2 (en)
CA (2) CA3113689A1 (en)
CL (2) CL2021000731A1 (en)
IL (2) IL281770A (en)
MA (2) MA53707A (en)
MX (2) MX2021003498A (en)
SG (2) SG11202102790PA (en)
WO (2) WO2020064174A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020064174A1 (en) * 2018-09-25 2020-04-02 Antabio Sas Indane derivatives for use in the treatment of bacterial infection
US20240016941A1 (en) * 2020-03-24 2024-01-18 Antabio Sas Combination therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457196A (en) * 1991-09-27 1995-10-10 Merrell Dow Pharmaceuticals Inc. 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
JP3126541B2 (en) * 1993-03-26 2001-01-22 千寿製薬株式会社 Benzothiazole derivatives, their preparation and their use
JPH0782259A (en) * 1993-09-14 1995-03-28 Senju Pharmaceut Co Ltd Succinamic acid derivative and medicine containing the same for therapy of diabetic complications
JPH11130761A (en) * 1997-10-24 1999-05-18 Otsuka Pharmaceut Co Ltd Benzothiazole derivative
CA2579221A1 (en) 2004-09-08 2006-03-16 Merck & Co., Inc. Monocyclic anilide spirolactam cgrp receptor antagonists
FR2883876B1 (en) 2005-03-30 2007-05-04 Servier Lab INDANYL-PIPERAZINE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
US7674507B2 (en) 2005-05-25 2010-03-09 Merck Patent Gmbh Pyran-dioxane derivatives, and the use thereof in liquid-crystalline media
MY154462A (en) 2007-06-05 2015-06-30 Sanofi Aventis Substituted benzoylamino-indan-2-carboxylic acids and related compounds
EP2141164A1 (en) 2008-07-01 2010-01-06 Mutabilis New 1,2,4-triazine derivatives and biological applications thereof
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US9775349B2 (en) * 2012-11-30 2017-10-03 Bayer Cropscience Ag Binary fungicidal or pesticidal mixture
GB201704476D0 (en) * 2017-03-21 2017-05-03 Antabio Sas Chemical compounds
WO2020064174A1 (en) * 2018-09-25 2020-04-02 Antabio Sas Indane derivatives for use in the treatment of bacterial infection

Also Published As

Publication number Publication date
US20220112169A1 (en) 2022-04-14
SG11202102791SA (en) 2021-04-29
CN113166085B (en) 2024-04-09
MX2021003498A (en) 2021-09-10
MA53706A (en) 2021-12-29
BR112021005532A2 (en) 2021-06-29
CN113166084B (en) 2024-06-04
KR20210087025A (en) 2021-07-09
SG11202102790PA (en) 2021-04-29
CL2021000729A1 (en) 2021-11-05
KR20210087448A (en) 2021-07-12
WO2020064174A1 (en) 2020-04-02
IL281780A (en) 2021-05-31
US20210347748A1 (en) 2021-11-11
CA3113689A1 (en) 2020-04-02
EP3856730A1 (en) 2021-08-04
JP2022502486A (en) 2022-01-11
AU2019351551A1 (en) 2021-04-15
CN113166084A (en) 2021-07-23
CL2021000731A1 (en) 2021-11-05
MX2021003485A (en) 2021-09-10
JP7429992B2 (en) 2024-02-09
JP2022502485A (en) 2022-01-11
JP7429993B2 (en) 2024-02-09
BR112021005651A2 (en) 2021-06-22
WO2020064173A1 (en) 2020-04-02
MA53707A (en) 2021-12-29
EP3856729A1 (en) 2021-08-04
CA3113697A1 (en) 2020-04-02
AU2019349438A1 (en) 2021-04-15
CN113166085A (en) 2021-07-23

Similar Documents

Publication Publication Date Title
EP3838239A4 (en) Medical dressing
EP3390357A4 (en) Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections
IL271863B (en) Compounds and use thereof for the treatment of microbial infections
EP3576738A4 (en) Use of gaboxadol in the treatment of tinnitus
ZA202103977B (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
IL264232A (en) Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections
IL281775A (en) Methods of treatment of infections using bacteria
IL278895A (en) Diltiazem for use in the treatment of microbial infections
ZA202002069B (en) Novel mek-inhibitor for the treatment of viral and bacterial infections
IL281770A (en) Indane derivatives for use in the treatment of bacterial infection
HK1243951A1 (en) Antimicrobial combinations and their use in the treatment of microbial infection
PL3497095T3 (en) Zinc chelating compounds for use in the treatment of bacterial infection
EP3761979A4 (en) Use of gaboxadol in the treatment of substance use disorders
EP3285787B8 (en) Treatment of bacterial infections in aquaculture
DK3630111T3 (en) Compounds and methods for treating bacterial infections
EP3856747C0 (en) Substituted pyridoindoles for the treatment and prophylaxis of bacterial infection
EP3609578A4 (en) Pharmaceutical combination and its use for treating synucleinopathies
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
IL253418A0 (en) Nisin-based compounds and use thereof in the treatment of bacterial infections
EP3694391A4 (en) Device for use in the treatment of hemorrhoids
PL3618806T3 (en) Compositon for the treatment of aphthas and mouth ulcers
EP3538094A4 (en) Formulations, methods, kit, and dosage forms for treating bacterial infection
IL281969A (en) New medical use of oxalate-reducing bacteria
EP3579843A4 (en) 3-beta-hydroxy-5-alpha-pregnan-20-one for use in medical treatment